CYP24A1 and prostate carcinoma: In vitro and in vivo studies also showed that CYP24A1 has been deemed as a candidate oncogene in many cancers, such as ovarian cancer (35), colorectal cancer (36, 37), prostate cancer (38), lung cancer (39), breast cancer (40), thyroid cancer (41), and so on.